Svitlana Tyekucheva

The prostate stromal transcriptome in aggressive and lethal prostate cancer.

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.

Mol Cancer Res. 2022 Dec 13. PMID: 36511902

Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?

Zhou CD, Pettersson A, Plym A, Tyekucheva S, Penney KL, Sesso HD, Kantoff PW, Mucci LA, Stopsack KH.

Cancer Prev Res (Phila). 2022 12 01. 15(12):815-825. PMID: 36125434

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.

Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petrácková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR.

J Clin Oncol. 2022 Oct 31. JCO2200269. PMID: 36315919

Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance.

Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR.

Blood Adv. 2022 Oct 26. PMID: 36287227

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.

Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM.

JAMA Oncol. 2022 08 01. 8(8):1177-1183. PMID: 35737367

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.

Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR.

Br J Haematol. 2022 04. 197(2):207-211. PMID: 35170759

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM.

Eur J Cancer. 2022 03. 164:39-51. PMID: 35172272

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.

Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR.

Blood. 2022 02 03. 139(5):686-689. PMID: 34788401

Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.

Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA.

Elife. 2021 12 23. 10. PMID: 34939926

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.

Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR.

Leukemia. 2022 03. 36(3):723-732. PMID: 34743191